Detalhe da pesquisa
1.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J
; 267: 1-11, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758044
2.
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
Cardiovasc Diabetol
; 23(1): 63, 2024 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341541
3.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet
; 398(10313): 1811-1824, 2021 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672967
4.
Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.
Diabetes Care
; 47(6): 1020-1027, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530948
5.
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Diabetes Ther
; 14(11): 1833-1852, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526908
6.
Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis.
Diabetes Care
; 46(8): 1501-1506, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37267479
7.
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Nat Med
; 28(3): 591-598, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35210595
8.
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Lancet Diabetes Endocrinol
; 10(11): 774-785, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152639
9.
Ubiquitous GFP expression in transgenic chickens using a lentiviral vector.
Development
; 132(5): 935-40, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15673573